| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K/A |
| Revenues: |
| Total revenues [+] | 11.2 | 8.9 | 13.9 | 11.3 | 7.4 | 14.2 | 8.7 | 5.3 |
| Products | | | | | | 13.4 | 4.4 | |
| Services | | | | | | 0.8 | 4.3 | |
| Revenue growth [+] | 26.6% | -36.2% | 22.8% | 54.1% | -48.3% | 64.2% | 62.6% | 61.3% |
| EksoHealth | 20.9% | -32.5% | 35.0% | 51.8% | | | | |
| Cost of goods sold [+] | 4.5 | 3.8 | 7.2 | 7.0 | 5.3 | 11.3 | 7.5 | 3.8 |
| Cost of product sales | | | | | | 10.7 | 3.9 | |
| Cost of services | | | | | | 0.6 | 3.6 | |
| Gross profit | 6.7 | 5.1 | 6.8 | 4.3 | 2.1 | 2.9 | 1.2 | 1.6 |
| Gross margin | 60.0% | 57.1% | 48.6% | 38.0% | 28.1% | 20.7% | 13.6% | 29.3% |
| Selling, general and administrative [+] | 17.8 | 15.5 | 18.8 | 25.5 | 23.9 | 21.9 | 16.3 | 14.5 |
| Sales and marketing | 7.3 | 7.8 | 11.4 | 13.8 | 13.2 | 11.0 | 9.3 | 7.1 |
| General and administrative [+] | 10.5 | 7.7 | 7.4 | 11.7 | 10.7 | 10.9 | 7.0 | 7.4 |
| General and administrative expenses | 10.5 | 7.7 | 7.4 | 11.7 | 10.7 | 10.9 | 7.0 | 7.4 |
| Research and development | 2.7 | 2.5 | 4.6 | 5.8 | 9.5 | 8.9 | 6.5 | 3.9 |
| Other operating expenses | | | | | 0.3 | -0.2 | | |
| EBITDA [+] | -13.3 | -12.2 | -15.9 | -25.4 | -29.9 | -25.7 | -20.6 | -16.0 |
| EBITDA growth | 8.4% | -23.0% | -37.4% | -15.1% | 16.1% | 24.7% | 28.5% | 63.3% |
| EBITDA margin | -118.0% | -137.8% | -114.1% | -223.8% | -406.1% | -180.9% | -238.2% | -301.3% |
| Depreciation | 0.6 | 0.6 | 0.8 | 1.7 | 1.2 | 1.3 | 0.9 | 0.7 |
| EBITA | -13.8 | -12.9 | -16.6 | -27.0 | -31.1 | -27.0 | -21.5 | -16.8 |
| EBITA margin | -123.0% | -144.8% | -119.6% | -238.5% | -422.6% | -190.1% | -248.6% | -315.3% |
| Amortization of intangibles | | | | | 0.5 | 0.6 | 0.0 | |
| EBIT [+] | -13.8 | -12.9 | -16.6 | -27.0 | -31.6 | -27.6 | -21.6 | -16.8 |
| EBIT growth | 7.5% | -22.7% | -38.4% | -14.5% | 14.6% | 27.9% | 28.4% | 63.1% |
| EBIT margin | -123.0% | -144.8% | -119.6% | -238.5% | -429.9% | -194.0% | -248.9% | -315.3% |
| Non-recurring items [+] | | 0.4 | | | | | | |
| Asset impairment | | 0.2 | | | | | | |
| Interest expense, net [+] | 0.1 | 0.1 | 0.4 | 0.6 | 0.6 | 0.0 | 0.0 | 0.4 |
| Interest expense | 0.1 | 0.1 | 0.4 | 0.6 | 0.6 | 0.0 | 0.0 | 0.4 |
| Interest income | | | | | | 0.0 | 0.0 | 0.0 |
| Other income (expense), net [+] | 4.2 | -2.4 | 4.9 | 0.6 | 3.1 | 4.1 | 2.0 | -16.5 |
| Change in fair value of warrants | 1.0 | | | | | | | |
| Other | -0.9 | 1.0 | -0.1 | -0.4 | 0.3 | -0.2 | 0.0 | |
| Pre-tax income | -9.8 | -15.8 | -12.1 | -27.0 | -29.1 | -23.5 | -19.6 | -33.8 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -9.8 | -15.8 | -12.1 | -27.0 | -29.1 | -33.8 | -24.2 | 0.0 |
| Net margin | -86.8% | -178.2% | -87.2% | -238.2% | -396.1% | -237.8% | -279.9% | -0.6% |
| |
| Basic EPS [+] | ($0.80) | ($2.21) | ($2.53) | ($0.44) | ($0.82) | ($1.87) | ($1.66) | ($3.02) |
| Growth | -63.7% | -12.7% | 474.1% | -46.1% | -56.2% | 12.4% | -45.0% | 433.0% |
| Diluted EPS [+] | ($0.80) | ($2.21) | ($2.53) | ($0.44) | ($0.82) | ($1.82) | ($1.66) | ($3.02) |
| Growth | -64.0% | -12.7% | 474.1% | -46.1% | -55.0% | 9.4% | -45.1% | 433.0% |
| |
| Shares outstanding (basic) [+] | 12.2 | 7.2 | 4.8 | 61.2 | 35.6 | 18.1 | 14.6 | 0.0 |
| Growth | 70.2% | 49.4% | -92.2% | 71.9% | 96.5% | 24.1% | 130532.3% | -99.9% |
| Shares outstanding (diluted) [+] | 12.3 | 7.2 | 4.8 | 61.2 | 35.6 | 18.6 | 14.6 | 0.0 |
| Growth | 71.3% | 49.4% | -92.2% | 71.9% | 91.2% | 27.5% | 130559.2% | -99.9% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |